Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase NA 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 8NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1Dermatologic 1

Conditions

Central Nervous System Neoplasms 2Melanoma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NIH × O(6)-benzylguanine × Clear all
NCT00275002 2022-02-11

O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 9 charts
CNS

Central Nervous System Neoplasms

NCT00436436 2017-03-28

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
12 enrolled 10 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00005961 2013-02-11

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡